Clinical trials & pipeline

We are advancing a diverse and promising portfolio of clinically differentiated compounds through internal development and strategic external partnerships.

Phase 3
STELLAR-304
Non-Clear Cell Renal Cell Carcinoma
Phase 3
STELLAR-303
Colorectal Cancer
Phase 1A
JEWEL-101
Multiple Solid Tumors
Phase 1A

Cybrexa Therapeutics+

Multiple Solid Tumors
Phase 1A

Sairopa*

Multiple Solid Tumors
Asset/Program
  • Discovery/Preclinical Disc/Pre
  • IND IND
  • Phase 1A Phase 1A
  • Phase 1B Phase 1B
  • Phase 2/3 Phase 2/3
Phase 2/3

CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023

CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023

Multi-TKI targeting MET/VEGFR/AXL/RET

Multi-TKI targeting MET/VEGFR/AXL/RET

Phase 2/3

CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023

CONTACT-02 (mCRPC): Complete enrollment and report pivotal top-line PFS data in second half 2023

Phase 2/3

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023

COSMIC-313 (Advanced intermediate- or poor-risk first-line RCC): Report OS analysis by year-end 2023

Phase 2/3 and Phase 1B

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

STELLAR-303 (CRC)

STELLAR-303 (CRC)

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

XL092; Next-generation TKI targeting MET/VEGFR/AXL/MER

Phase 2/3

STELLAR-304 (nccRCC)

STELLAR-304 (nccRCC)

Phase 2/3

STELLAR-303 (CRC)

STELLAR-303 (CRC)

Phase 1B

STELLAR-002 (Solid tumors)

STELLAR-002 (Solid tumors)

Phase 1B

STELLAR-001 (Solid tumors)

STELLAR-001 (Solid tumors)

Phase 1A

JEWEL-101 (Solid tumors)

JEWEL-101 (Solid tumors)

Next-generation TF-targeting ADC

Next-generation TF-targeting ADC

Phase 1A

JEWEL-101 (Solid tumors)

JEWEL-101 (Solid tumors)

Phase 1A

QUARTZ-101 (Solid tumors)

QUARTZ-101 (Solid tumors)

Oral CDK7 inhibitor

Oral CDK7 inhibitor

Phase 1A

QUARTZ-101 (Solid tumors)

QUARTZ-101 (Solid tumors)

Phase 1A
Cybrexa Therapeutics+

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

Peptide-drug conjugate

Peptide-drug conjugate

Phase 1A

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

Phase 1A
Sairopa*

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

SIRPα-targeting mAb

SIRPα-targeting mAb

Phase 1A

Option to acquire asset pending certain phase 1 results (Solid tumors)

Option to acquire asset pending certain phase 1 results (Solid tumors)

Discovery/Preclinical

Next-generation 5T4-targeting ADC

Next-generation 5T4-targeting ADC

Discovery/Preclinical
Discovery/Preclinical

Bispecific antibody targeting PD-L1 + CD47

Bispecific antibody targeting PD-L1 + CD47

Discovery/Preclinical
Discovery/Preclinical

Bispecific antibody targeting PD-L1 + NKG2A

Bispecific antibody targeting PD-L1 + NKG2A

Discovery/Preclinical
Discovery/Preclinical

Next-generation TF-topoisomerase ADC

Next-generation TF-topoisomerase ADC

Discovery/Preclinical
Discovery/Preclinical

Non-disclosed

Non-disclosed

Discovery/Preclinical
Discovery/Preclinical

Non-disclosed

Non-disclosed

Discovery/Preclinical

ADAR1

ADAR1

Discovery/Preclinical
Discovery/Preclinical

PKMYT1 inhibitors

PKMYT1 inhibitors

Discovery/Preclinical
Discovery/Preclinical
Invenra, NBE Therapeutics, Catalent, GamaMabs, WuXi, Adagene, BioInvent and Ryvu Theraputics Collaborations

AMHR2, ROR1/2, TF, DLL3

AMHR2, ROR1/2, TF, DLL3

Discovery/Preclinical

You are now leaving the exelixis.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.